Literature DB >> 23485771

Prevalence and type distribution of human papillomavirus in cervical adenocarcinoma in Korean women.

Jong-Sup Park1, Young-Tak Kim, Ahwon Lee, Yonghee Lee, Ki-Tae Kim, Chi-Heum Cho, Ho-Sun Choi, David Jenkins, Edyta C Pirog, Anco C Molijn, Gunasekaran Ramakrishnan, Jing Chen.   

Abstract

BACKGROUND: An increase in incidence of cervical adenocarcinoma (CADC) has been reported in many countries, including Korea. However, few studies describe human papillomavirus (HPV) type distribution among CADC in Asia. OBJECTIVE AND METHODS: This was a retrospective, hospital-based observational study between 2005 and 2010 to estimate the overall prevalence and distribution of HPV types among CDAC in Korean women. The study used hematoxylin & eosin and immunohistochemical staining (for the two biomarkers p16 and progesterone receptor [PR]) to diagnose and subtype CADC samples. HPV DNA was amplified by polymerase chain reaction (PCR) and HPV genotypes were identified using reverse hybridization.
RESULTS: Of 196 cases submitted, 89.3% of the cases were confirmed as CADC. The mean age at diagnosis was 47.1 (standard deviation [SD] 11.9) years. No statistically significant differences in mean age at diagnosis by histological subtype were found. HPV DNA was detected in 90.3% (177/196) of CADC. HPV-18 was the most prevalent type (54.2%), followed by HPV-16 (44.1%) and HPV-45 (3.4%). Infection with any high-risk HPV type was identified in 97.7% of HPV-DNA-positive CADC. The biomarker p16 was positive in 92% of CADC cases and PR was positive in 19.6% of CADC.
CONCLUSION: HPV DNA was found in the large majority of CADC in Korean women, with HPV-18 being the most common type followed by HPV-16 and HPV-45. This study is among the first in Asia to specifically report HPV type distribution in CADC. This information will help inform policy decisions concerning HPV vaccination for the prevention of CADC.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23485771     DOI: 10.1016/j.ygyno.2013.02.026

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  5 in total

Review 1.  Invasive stratified mucin-producing carcinoma (i-SMILE) of the uterine cervix: report of a case series and review of the literature indicating poor prognostic subtype of cervical adenocarcinoma.

Authors:  Lars-Christian Horn; Romy Handzel; Gudrun Borte; Udo Siebolts; Anja Haak; Christine E Brambs
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-05       Impact factor: 4.553

2.  Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study.

Authors:  Katsiaryna Holl; Andrzej M Nowakowski; Ned Powell; W Glenn McCluggage; Edyta C Pirog; Sabrina Collas De Souza; Wiebren A Tjalma; Mats Rosenlund; Alison Fiander; Maria Castro Sánchez; Vasileia Damaskou; Elmar A Joura; Benny Kirschner; Robert Koiss; John O'Leary; Wim Quint; Olaf Reich; Aureli Torné; Michael Wells; Lukas Rob; Larisa Kolomiets; Anco Molijn; Alevtina Savicheva; Elena Shipitsyna; Dominique Rosillon; David Jenkins
Journal:  Int J Cancer       Date:  2015-07-14       Impact factor: 7.396

3.  Human papillomavirus genotypes in Pacific Islander cervical cancer patients.

Authors:  T M Schisler; A K Bhavsar; B P Whitcomb; J H Freeman; M A Washington; J W Blythe; M A Nahid; C S Dietrich
Journal:  Gynecol Oncol Rep       Date:  2018-04-18

4.  Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination.

Authors:  Jeanne M Pimenta; Claudia Galindo; David Jenkins; Sylvia M Taylor
Journal:  BMC Cancer       Date:  2013-11-21       Impact factor: 4.430

5.  Persistence, clearance and reinfection regarding six high risk human papillomavirus types in Colombian women: a follow-up study.

Authors:  Sara C Soto-De León; Luisa Del Río-Ospina; Milena Camargo; Ricardo Sánchez; Darwin A Moreno-Pérez; Antonio Pérez-Prados; Manuel E Patarroyo; Manuel A Patarroyo
Journal:  BMC Infect Dis       Date:  2014-07-16       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.